article · Arthritis & Rheumatology
Vacuoles E1 enzyme X-linked autoinflammatory somatic syndrome, known as VEXAS, is a newly recognised rare genetic condition linked to somatic mutations in the UBA1 gene. The disorder causes a complex combination of inflammatory and haematologic signs that result in higher morbidity and mortality. Because disease presentations vary widely and relevant literature remains scarce, clinicians have lacked structured guidelines for patient management. To resolve this issue, an international panel of multidisciplinary specialists convened through formalised sessions and voting procedures to build a consensus framework. The resulting guidance offers actionable advice covering disease characteristics, methods for screening UBA1 mutations, diagnostic approaches for concurrent myelodysplastic syndromes, and key factors in determining prognosis and therapeutic strategies. This statement stands as the initial international consensus document designed to assist practitioners in managing the condition.
VEXAS syndrome is a severe, newly discovered disease that combines blood and inflammatory disorders, carrying serious health risks. Providing the first unified international medical guidance gives doctors clear rules on which patients should undergo genetic screening, how to interpret related blood disorders, and how to approach treatment, leading to better diagnostic consistency.
This work establishes clinical guidance rather than a commercial product, but it directly informs the diagnostic and clinical testing pathways that healthcare systems and diagnostic laboratories follow. It provides near-market utility for clinical practitioners needing clear protocols for UBA1 screening and patient evaluation. Beyond standardising diagnostic decision-making for clinicians, the abstract does not indicate any direct product commercialisation pathway.
AI-generated from the published abstract. Always read the original work before citing.
OBJECTIVE: Vacuoles E1 enzyme X-linked autoinflammatory somatic syndrome (VEXAS) is a recently identified rare genetic disorder associated with somatic mutations in the UBA1 gene. VEXAS presents with a combination of inflammatory and hematologic manifestations, leading to increased morbidity and mortality. METHODS: Given the variability in disease presentation and the limited number of studies to date, no clinical documents currently exist to provide guidance to health care providers about the management of VEXAS. To address this gap, we formed an international multidisciplinary panel of VEXAS experts. RESULTS: Through formalized meetings and a voting process, the group developed consensus clinical guidance considerations for the management of VEXAS. These considerations offer practical advice on several key topics: (1) clinical features of VEXAS, (2) UBA1 screening methods, (3) the diagnosis of myelodysplastic syndromes (MDSs) in patients with VEXAS, and (4) prognosis and management. The aim is to provide expert guidance on which patients to test, how to test for VEXAS, how to approach MDS in the context of VEXAS, and considerations for management. CONCLUSION: This work marks the first formal international consensus guidance for VEXAS and is intended to be used as a resource for clinicians seeking to understand the disease and its management.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1002/art.43287
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
